Post-SARS-CoV-2 Acute Telogen Effluvium: An Expected Complication

Post-SARS-CoV-2 telogen effluvium has been described in case reports of COVID-19 patients. We evaluated the prevalence of post-SARS-CoV-2 telogen effluvium in patients from a single medical center, exploring any causal links with the infection. Our hospital-based, cross-sectional study was conducted...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical medicine Vol. 11; no. 5; p. 1234
Main Authors Monari, Paola, Gualdi, Giulio, Bettoni, Giorgio, Costa, Raffaella, Ragni, Giorgio, Zani, Francesca, Bianchi, Giovanna, Casella, Silvia, Casella, Elisa, Crippa, Massimo, Calzavara Pinton, Piergiacomo, Di Nicola, Marta, Porreca, Annamaria, Amerio, Paolo, Guizzi, Pierangelo
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 24.02.2022
MDPI
Subjects
Alopecia
Baldness
Clinical medicine
Coronaviruses
COVID-19
Cytokines
Dengue fever
Disease
Epidemics
Hair loss
Hospitalization
Infections
Inflammation
Intensive care
Laboratories
Patients
Pneumonia
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
telogen effluvium
COVID-19
SARS-CoV-2
telogen effluvium
alopecia
Online AccessGet full text

Cover

More Information
Summary:Post-SARS-CoV-2 telogen effluvium has been described in case reports of COVID-19 patients. We evaluated the prevalence of post-SARS-CoV-2 telogen effluvium in patients from a single medical center, exploring any causal links with the infection. Our hospital-based, cross-sectional study was conducted with patient participants discharged with a diagnosis of SARS-CoV-2 pneumonia from 1 March to 4 April 2020. All patients were evaluated by the same senior dermatologist; a clinical/dermatoscopic evaluation was performed. Alopecia was assessed in 31.3% of patients, with a significant difference in sex (females 73%, males 26.7%). The average time detected from the onset of the first symptoms to alopecia was 68.43 days. Overall, there were no significant associations between alopecia and COVID-19-related features (length of hospitalization, virologic positivity, or duration of fever), treatment characteristics, or laboratory findings. In this paper, we report that post-infection acute telogen effluvium occurs in a significant number of COVID-19 patients. The burden of this condition may impair the quality of life, with a significant impact on individuals.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally to this work.
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm11051234